Replies to post #67609 on Biotech Values

[DewDiligence]

ELN/BIIB – Forbes needs a better calculator:

http://www.forbes.com/2008/10/21/biogen-idec-biotech-markets-equity-cx_lal_1021markets24.html

>>
As of the end of September, more than 35,500 patients were on Tysabri, the mulitple sclerosis drug in question, down from 31,800 at the end of the second quarter.
<<

:- )